CDK2 and acute lymphoblastic leukemia: To further investigate the molecular basis by which CB2 and TRPV1 agonists inhibited the G0/G1 transition in T-ALL, we also analyzed the expression of CDK2 mRNA and the active form of the protein pCDK2.